c

Tirzepatide subcutaneous injection for type 2 diabetes

24th March 2024 by Dr Louise Hudman

Tirzepatide subcutaneous injection for type 2 diabetes

NICE released guidance on the use of tirzepatide for diabetes in October 2023.

What is tirzepatide?

Tirzepatide is an agonist at both the GLP-1 receptor (glucagon-like peptide 1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). Stimulation of these receptors causes an increase in the release of GLP-1 and GIP and these in turn cause an increased release of insulin, a reduced glucagon release and delayed gastric emptying.

It both improves diabetes control and increases weight loss.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

Related content

"A must-have for any GP locum.

I have used NASGP website since I started locuming three years ago. It caters for all my locum needs, and I found LocumDeck particularly useful for bookings and invoicing. The automatically-generated invoices and pension forms save me countless hours of admin time every month, and the recently introduced e-signed forms are brilliant.

The assistance I have received has always been quick and helpful. The forums and updates have also kept me in the loop with important issues which may affect my practice.

I cannot recommend this website enough. "

Dr Suzanne Gaskell, GP

Dr Suzanne Gaskell, GP

See the full list of features within our NASGP membership plans

Membership